Dupilumab for COPD Phase 3 Trial Results: CHEST 2024
Findings from two Phase 3 clinical trials, BOREAS and NOTUS, revealed that dupilumab, a monoclonal antibody targeting key drivers of type 2 inflammation, improves health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD)